healthcare

Annabelle Miller, Armina Rosenberg and Dawn Kanelleas share their top ideas heading into the new year.

Markets split between costly AI and undervalued sectors. Vaccine makers offer cheap valuations and steady income amid uncertainty.

A decade of rising utilisation is coming. Anna Milne outlines the forces reshaping healthcare and the stocks positioned to win.

Policy clarity, increased M&A, and solid earnings have made global healthcare attractive for investors seeking to fortify portfolios.

After years of flawless growth, CSL’s streak has broken. So, what's next for this fallen titan of the Australian corporate landscape?

From nuclear microreactors to AI-powered medicine, these ASX and international early-stage companies are drawing serious investor interest.

With our fund up 35%+ in six months, we're looking at undervalued healthcare opportunities in the market to drive future returns.

After announcing soft guidance, a spin off of its vaccines unit, and plans to cut 3000 jobs, investors are pondering CSL's future.

Penumbra's aspiration-based mechanical thrombectomy devices are building one of the most defensible competitive moats in medical technology

In a sector where utilisation and reimbursement are tightly linked, reduction in admin drag supports more stable, visible revenue streams.